/CHRS

Coherus Oncology Inc

CHRS

$1.40USD↑+0.72%+0.01 today

MARKET CAP

215.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$3

AI Summary

Stalk

TrimMedium

CHRS remains in a Stage 4 decline with a confirmed LH/LL regime and price below downward-sloping EMAs, supporting a medium-term bearish bias. The recent bounce into the 9/21EMA zone lacks follow-through, making immediate selling unfavorable. We defer execution, trimming into rallies at EMAs and prior resistance areas rather than chasing current extension.

↑Q1 2026 Lactorsi revenue rose 61% YoY to $11.8M, fueled by a 21% increase in new patient starts.
↑Management projects Lactorsi will reach $15M quarterly by late 2026 and $175M in annual sales by 2028.
↓June 2026 downgrade followed Q2 EPS estimate cut from $0.08 to -$0.12, undermining investor confidence.

Full analysis →

Min Company Value

AI View

Min Insiders / Ticker

Hide Automated (10b5-1)

Date Range

Insider Trades18 trades

Date↓	Side	Ticker↕	Insider↕	Role↕	Shares↕	Price↕	Mkt Cap↕	52W High↕	52W Low↕	Value↕	% Chg↕	Rule↕	AI View↕
Jan 20, 2026	Sell	CHRS	Bryan J Mcmichael	Chief Financial Officer	1,715	$1.55	$215.9M	-46.48%	+72.84%	$2.7K	-7.47%	—	Trim
Jan 20, 2026	Sell	CHRS	Dennis M Lanfear	President & CEO	11,839	$1.55	$215.9M	-46.48%	+72.84%	$18.4K	-1.73%	—	Trim
Jan 20, 2025	Sell	CHRS	Bryan J Mcmichael	Chief Financial Officer	1,711	$1.39	$215.9M	-46.48%	+72.84%	$2.4K	-6.94%	—	Trim
Jan 20, 2025	Sell	CHRS	Paul Reider	Chief Commercial Officer	4,858	$1.39	$215.9M	-46.48%	+72.84%	$6.8K	-5.59%	—	Trim
Jan 20, 2025	Sell	CHRS	Dennis M Lanfear	President & CEO	11,810	$1.39	$215.9M	-46.48%	+72.84%	$16.4K	-1.69%	—	Trim
Jan 7, 2025	Sell	CHRS	Bryan J Mcmichael	Chief Financial Officer	1,711	$1.57	$215.9M	-46.48%	+72.84%	$2.7K	-6.49%	—	Trim
Jan 4, 2025	Sell	CHRS	Paul Reider	Chief Commercial Officer	2,277	$1.66	$215.9M	-46.48%	+72.84%	$3.8K	-0.91%	—	Trim
Jan 4, 2025	Sell	CHRS	Dennis M Lanfear	President & CEO	11,810	$1.66	$215.9M	-46.48%	+72.84%	$19.6K	-1.67%	—	Trim
Dec 13, 2024	Sell	CHRS	Paul Reider	Chief Commercial Officer	2,073	$1.61	$215.9M	-46.48%	+72.84%	$3.3K	-2.27%	—	Trim
Jan 20, 2024	Sell	CHRS	Bryan J Mcmichael	—	1,707	$2.44	$215.9M	-46.48%	+72.84%	$4.2K	-6.92%	—	Trim
Jan 20, 2024	Sell	CHRS	Paul Reider	Chief Commercial Officer	4,854	$2.44	$215.9M	-46.48%	+72.84%	$11.8K	-5.64%	—	Trim
Jan 20, 2024	Sell	CHRS	Dennis M Lanfear	President & CEO	11,218	$2.44	$215.9M	-46.48%	+72.84%	$27.4K	-1.56%	—	Trim
Jan 7, 2024	Sell	CHRS	Bryan J Mcmichael	—	1,707	$2.87	$215.9M	-46.48%	+72.84%	$4.9K	-6.47%	—	Trim
Jan 4, 2024	Sell	CHRS	Paul Reider	Chief Commercial Officer	2,275	$2.92	$215.9M	-46.48%	+72.84%	$6.6K	-2.57%	—	Trim
Jan 4, 2024	Sell	CHRS	Dennis M Lanfear	President & CEO	11,781	$2.92	$215.9M	-46.48%	+72.84%	$34.4K	-0.90%	—	Trim
Dec 31, 2023	Sell	CHRS	Mcdavid Stilwell	Chief Financial Officer	18,440	$3.33	$215.9M	-46.48%	+72.84%	$61.4K	-19.67%	—	Trim
Dec 13, 2023	Sell	CHRS	Paul Reider	Chief Commercial Officer	2,049	$2.37	$215.9M	-46.48%	+72.84%	$4.9K	-2.27%	—	Trim
Nov 22, 2023	Buy	CHRS	Dennis M Lanfear	President & CEO	523,040	$1.67	$215.9M	-46.48%	+72.84%	$874.8K	+3.33%	—	Trim